USPTO 2015–2025 USPTO PatentsView US Corporation

Novozymes, Inc.

USPTO PatentsView assignee record — 208 granted patents across 24 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

208
Total patents granted
24
CPC technology areas
26.0
Avg claims per patent
-82%
5-year filing velocity

Portfolio overview

Novozymes, Inc. has been granted 208 US utility patents between 2015 and 2025, placing Novozymes, Inc. at rank #1,932 across all assignees tracked by PlainPatent. This portfolio spans 24 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.0 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Novozymes, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 51.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 32 grants, compared with 176 in the 2015–2019 window — a -82% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Novozymes, Inc.'s 26.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while a multi-domain presence across 24 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Novozymes, Inc. against peers pursuing similar technology classes.

How does Novozymes compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Novozymes holds 208 patents — placing it at rank #1,932 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

-1001020304050 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Novozymes, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 36 17.3%
2016 38 18.3%
2017 41 19.7%
2018 36 17.3%
2019 25 12.0%
2020 13 6.3%
2021 11 5.3%
2022 3 1.4%
2023 1 0.5%
2024 1 0.5%
2025 3 1.4%

Which technologies does Novozymes, Inc. patent most?

Top 15 of 24 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Complex
Velocity Declining

Where it ranks

Overall rank by patents

#1,932

Across all tracked assignees

Innovation Score

51.5 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Novozymes, Inc. hold?
Novozymes, Inc. holds 208 US granted patents filed between 2015 and 2025, spanning 24 technology areas.
What is Novozymes, Inc.'s Innovation Score?
Novozymes, Inc. has an Innovation Score of 51.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Novozymes, Inc. focus on?
Novozymes, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 199 patents. The company has filed patents in 24 CPC subclasses total.
Is Novozymes, Inc.'s patent filing rate increasing or decreasing?
Novozymes, Inc.'s recent filing velocity is -82% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Novozymes, Inc.'s patents?
Novozymes, Inc.'s patents average 26.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Novozymes, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope